Sector Gamma AS raised its position in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 117.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 172,978 shares of the biopharmaceutical company’s stock after purchasing an additional 93,325 shares during the quarter. Ultragenyx Pharmaceutical comprises 1.3% of Sector Gamma AS’s portfolio, making the stock its 29th largest holding. Sector Gamma AS owned about 0.30% of Ultragenyx Pharmaceutical worth $7,400,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. NumerixS Investment Technologies Inc acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $25,000. Cutler Group LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $31,000. First Mercantile Trust Co. lifted its holdings in shares of Ultragenyx Pharmaceutical by 16.9% in the second quarter. First Mercantile Trust Co. now owns 1,151 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 166 shares in the last quarter. Smith Asset Management Group LP lifted its holdings in shares of Ultragenyx Pharmaceutical by 22.6% in the second quarter. Smith Asset Management Group LP now owns 1,680 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 310 shares in the last quarter. Finally, CSat Investment Advisory L.P. purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $114,000.
A number of research firms have recently issued reports on RARE. Wedbush restated a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 15th. Piper Jaffray Companies set a $75.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, September 4th. Citigroup reduced their target price on Ultragenyx Pharmaceutical from $66.00 to $45.00 and set a “neutral” rating for the company in a report on Thursday. BidaskClub lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $75.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $71.92.
Shares of NASDAQ:RARE traded up $1.40 during midday trading on Friday, hitting $38.90. 481,700 shares of the stock were exchanged, compared to its average volume of 546,206. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.14 and a current ratio of 9.32. The business’s fifty day simple moving average is $42.04 and its two-hundred day simple moving average is $54.48. Ultragenyx Pharmaceutical Inc has a 52-week low of $36.73 and a 52-week high of $74.50. The company has a market capitalization of $2.30 billion, a PE ratio of -5.26 and a beta of 2.15.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). The company had revenue of $25.80 million during the quarter, compared to the consensus estimate of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 51.40%. The firm’s quarterly revenue was up 119.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.74) EPS. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc will post -7.04 EPS for the current year.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis purchased 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was purchased at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the purchase, the chief executive officer now directly owns 472,479 shares in the company, valued at $20,614,258.77. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.80% of the stock is owned by company insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
See Also: What is a stock portfolio tracker?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.